Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ION775 (ApoC-III Silencing) in Severe Hypertriglyceridemia. The expected timing is based on the latest available company guidance and may change.
08/20/26:- ION775 Phase 1 12-month results to present at ESC 2026 Aug 28. Phase 2 ongoing.
Verification
Confirm timing and program details against the company announcement or filing.